VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1282-1290

  Uzunoglu, F G ^a   Kolbe, J ^a   Wikman, H ^b   Gungor C ^a   Bohn, B A ^a   Nentwich, M F ^a   Reeh, M ^a   Konig A M ^a   Bockhorn, M ^a   Kutup, A ^a   Mann, O ^a   Izbicki, J R ^a   Vashist, Y K ^a  

^a Visceral and Thoracic Surgery ^*  (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CXCR 2; Pancreatic cancer; PAR 1; Polymorphism; Tumor angiogenesis; VEGFR 2

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR2; CYTOSINE; ENDOSTATIN; PROTEINASE ACTIVATED RECEPTOR 1; THYMINE; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENOTYPE; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, PAR-1; RECEPTORS, INTERLEUKIN-8B; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877141830     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds634     Document Type: Article

References (31)

1. Van Ness B, Ramos C, Haznadar M et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
2. Reinmuth N, Parikh AA, Ahmad SA et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003; 60: 199-207.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
4. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3): 4-10.
5. Italiano JE Jr, Richardson JL, Patel-Hett S et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
6. Ma L, Perini R, McKnight W et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 2005; 102: 216-220.
7. Pinedo HM, Verheul HM, D'Amato RJ et al. Involvement of platelets in tumour angiogenesis?. Lancet 1998; 352: 1775-1777.
8. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
9. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
10. Assifi MM, Hines OJ. Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 2011; 11: 464-469.
11. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003; 2: 8.
12. Hansen TF, Sorensen FB, Spindler KL et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010; 456: 251-260.
13. Wang Y, Zheng Y, Zhang W et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007; 50: 760-767.
14. Glubb DM, Cerri E, Giese A et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 2011; 17: 5257-5267.
15. Kim DH, Xu W, Kamel-Reid S et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010; 21: 1179-1188.
16. Kidd LR, Brock GN, VanCleave TT et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control 2010; 21: 1545-1557.
17. Addison CL, Daniel TO, Burdick MD et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000; 165: 5269-5277.
18. Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 2009; 33: 710-715.
19. Matsuo Y, Raimondo M, Woodward TA et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027-1037.
20. Snoussi K, Mahfoudh W, Bouaouina N et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010; 10: 283.
21. Renzoni E, Lympany P, Sestini P et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000; 43: 1633-1640.
22. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
23. Ma L, Elliott SN, Cirino G et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001; 98: 6470-6475.
24. Lurje G, Husain H, Power DG et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010; 21: 78-86.
25. Lurje G, Leers JM, Pohl A et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010; 251: 857-864.
26. Arnaud E, Nicaud V, Poirier O et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-592.
27. Kamura T, Handa H, Hamasaki N et al. Characterization of the human thrombopoietin gene promoter. A possible role of an Ets transcription factor, E4TF1/GABP. J Biol Chem 1997; 272: 11361-11368.
28. Dupont A, Fontana P, Bachelot-Loza C et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003; 101: 1833-1840.
29. Iughetti P, Suzuki O, Godoi PH et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001; 61: 7375-7378.
30. Butturini G, Stocken DD, Wente MN et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: metaanalysis of randomized controlled trials. Arch Surg 2008; 143: 75-83; discussion 83.
31. Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 2009; 11: 282-289.